4 RESULTS
COMMENT I was unable to tune in for the hearing, but from what I have heard from colleagues, we are overall happy to see the committee’s approval. I understand the committee’s reasoning in not requiring tau PET. I also agree with Dr. Knopman’s point in his Alzfor
COMMENT These are exciting and stressful times in Alzheimer's research, and for those who care for patients with the disease. We are excited to have a new treatment after 18+ years, and to have the first treatment that may modify underlying disease processes
COMMENT This is a very interesting paper. It raises important questions about the heterogeneity of Alzheimer’s disease and the possible role of biomarkers in understanding the disease process. The cohort studied here, derived from a national prion disease registr
COMMENT authors did not comment on whether immunohistochemical stains for synuclein or ubiquitin were performed.
